Ascidian Therapeutics, a company developing RNA rewriting (or RNA exon editing) technology, announced a research collaboration and licensing agreement with Roche for the discovery and development of ...
-Interim readout expected in second half of 2025 and completion of Phase 1/2a study anticipated in 2026 CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a ...
KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERA TM platform Interim readout from REWRITE expected in the second half of 2025 Korro to advance additional pipeline ...
Roche has tapped the biotech start-up Ascidian Therapeutics to discover and develop RNA exon–editing medicines. Ascidian “rewrites” RNA by editing exons, parts of genes that form the nucleic acid, ...
The new CRISPR platform, called ΨDNA, reprograms Cas12 nucleases to recognize and act on RNA using a DNA-based guide scaffold ...
CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...
Korro Bio, Inc. announced that its investigational drug KRRO-110 has received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin Deficiency (AATD). This designation highlights the ...
Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, announced the completion of the adult dose escalation portion of the STELLAR phase 1/2 clinical trial ...
Korro Bio Inc.’s latest update on RNA editing prospect KRRO-110 may mean one less competitor in alpha-1 antitrypsin deficiency (AATD), and shares of the firm (NASDAQ:KRRO) closed Nov. 13 at $6.50, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results